Loading viewer...
investor_presentation
Format: PDF investor_presentation
Quidel Investor Presentation June 21, 2021
Quidel Investor Presentation
June 21, 20212 Copyright © 2021 Quidel Corporation. All rights reserved.Forward -Looking Statements
This presentation contains forward -looking statements within the meaning of the federal securities laws that involve material ri sks, assumptions and uncertainties. Many possible events or factors could affect our future
results and performance, such that our actual results and performance may differ materially from those that may be described or implied in the forward -looking statements. As such, no forward -looking statement can
be guaranteed. Differences in actual results and performance may arise as a result of a number of factors including, without limitation: the impact and duration of the COVID -19 global pandemic; competition from other
providers of diagnostic products; our ability to accurately forecast demand for our products and products in development, inc luding in new market segments; our ability to develop new technologies, products and
markets and to commercialize new products; our reliance on sales of our COVID -19 and influenza diagnostic tests; our reliance on a limited number of key distributors; quantity of our product in our distributors’
inventory or distribution channels; changes in the buying patterns of our distributors; the financial soundness of our custom ersand suppliers; lower than anticipated market penetration of our products; third -party
reimbursement policies and potential cost constraints; our ability to meet demand for our products; interruptions, delays or shortages in the supply of raw materials, components and other products and services;
failures in our information technology and storage systems; our exposure to data corruption, cyber -based attacks, security breac hes and privacy violations; international risks, including but not limited to, economic,
political and regulatory risks; continuing worldwide political and social uncertainty; our development, acquisition and prote ction of proprietary technology rights; intellectual property risks, including but not limited to,
infringement litigation; the loss of Emergency Use Authorizations for our COVID -19 products and failures or delays in receipt of reviews or regulatory approvals, clearances or authorizations for new products or related
to currently -marketed products by the U.S. Food and Drug Administration (the “FDA”) or other regulatory authorities or loss of a ny previously received regulatory approvals, clearances or authorizations or other
adverse actions by regulatory authorities; our contracts with government entities involve future funding, compliance and poss ible sanctions risks; product defects; changes in government policies and regulations and
compliance risks related thereto; our ability to manage our growth strategy and successfully identify, acquire and integrate potential acquisition targets or technologies and our ability to obtain financing; our acquisition
Preview truncated — download the full document for the complete content.
conference
27 Pages
investor_presentation
42 Pages
Schneider Electric
ClearSign Technologies Investor Presentation
investor_presentationinvestor_presentation
28 Pages
ClearSign Technologies Corporation
investor_presentation
8x8 Inc